SEP 10, 2020 10:20 PM PDT

Researchers Will Be Allowed To Use State-Licensed Cannabis for Research

WRITTEN BY: Angela Dowden

Cannabis researchers in the U.S. have often had their research efforts frustrated by the difficulties in being able to access marijuana and marijuana products. The problem has been that privately grown cannabis—even from state-licensed and compliant manufacturers—was not allowed in FDA-approved clinical trials. Instead, investigators were only allowed to obtain whole-plant cannabis from a single source: the University of Mississippi, which since 1968 was the only federally licensed source of cannabis cultivated for research purposes.

The good news is that change is afoot and quickly, following a September 9, 2020 vote by members of the House Energy and Commerce Committee to amend Congressman Earl Blumenauer’s HR 3797 bill: “The Marijuana Research Act of 2019”. The amended legislation expedites an approval process for newly-allowed federal cultivation applicants, and provides scientists with the option to utilize products manufactured by these state-licensed sources, not just the old official source.

 “The bipartisan support of our legislation in [this] committee mark-up is an important step in removing unnecessary barriers to medical cannabis research and ensuring that patients, clinicians, and consumers can fully understand the benefits and risks of cannabis,” Rep. Blumenauer said.

Deputy Director Paul Armentano from the National Organization for the Reform of Marijuana Laws (NORML) added that the new bill will “facilitate and expedite clinical cannabis research in the United States and provide important data regarding the safety and efficacy of real-world products.”

He added: “Rather than compelling scientists to access marijuana products of questionable quality manufactured by a limited number of federally licensed producers, federal regulators should allow investigators to access the cannabis and cannabis-infused products that are currently being produced in the legal marketplace by the multitude of state-sanctioned growers and retailers”.

Scientists have consistently criticized the poor quality of the University of Mississippi’s plants, which they say fail to accurately reflect the varieties of marijuana commercially available. For example scientists have only been able to select six varieties of pre-rolled cannabis cigarettes—none of which possess THC concentrations above seven percent—from the federal government’s marijuana menu, and tinctures and concentrates have not been available for clinical study at all.

Source: NORML

About the Author
  • I'm a Journalist and author with many year's experience of writing for both a consumer and professional audience, mostly on nutrition, health and medical prescribing. My background is food science and I'm a registered nutritionist.
You May Also Like
OCT 01, 2020
Cell & Molecular Biology
Signaling Waves Help Guide Cells to Heal Wounds
OCT 01, 2020
Signaling Waves Help Guide Cells to Heal Wounds
During development and throughout our lives, cells have to 'know' where to go to form the right structures and properly ...
OCT 04, 2020
Microbiology
A Virus Can Disrupt a Carb-Consuming Gut Microbe
OCT 04, 2020
A Virus Can Disrupt a Carb-Consuming Gut Microbe
Not all viruses affect animal cells; some viruses can infect bacteria. Humans are known to carry vast numbers of microor ...
OCT 06, 2020
Immunology
COVID Triggers Abnormalities in Immune Monocytes
OCT 06, 2020
COVID Triggers Abnormalities in Immune Monocytes
University of Manchester immunologists are the first to make an interesting observation about the white blood cells of p ...
OCT 09, 2020
Cannabis Sciences
Older Adults Use Cannabis for Common Health Problems
OCT 09, 2020
Older Adults Use Cannabis for Common Health Problems
Researchers from the University of California San Diego have found that older adults tend to use cannabis for medical pu ...
OCT 13, 2020
Cardiology
A Kidney Toxin Could Act as a Biomarker for Cardiovascular Risk
OCT 13, 2020
A Kidney Toxin Could Act as a Biomarker for Cardiovascular Risk
Biomarkers have taken the diagnostic field by storm over the past decade. The search for stable, easy to access indicato ...
OCT 29, 2020
Cardiology
Treating Cardiovascular Calcification at the Source
OCT 29, 2020
Treating Cardiovascular Calcification at the Source
The term cardiovascular disease covers a broad array of health problems. Everyone tends to think of heart attacks or hyp ...
Loading Comments...